Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Eur J Med Chem. 2013 Oct;68:312-20. doi: 10.1016/j.ejmech.2013.08.010. Epub 2013 Aug 13.

Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.

Author information

1
First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Road, Guangzhou 510120, China.

Abstract

The superposition of the DPP-IV complex revealed that the butynyl group of Linagliptin can be freely switched with the cyanobenzyl group of Alogliptin. Thus, a pharmacophore hybridization of Alogliptin was initiated and led to a novel DPP-IV inhibitor, 11a. Although it did not exhibit the desired activity (IC50=0.2 μM), compound 11a acts as a lead compound, which triggered a resulting structural optimization and the formation of compound 11m. A novel series of potent DPP-IV inhibitors represented by compound 11m (IC50=0.4 nM) was ultimately obtained with a robust pharmacokinetic profile and superior in vitro and in vivo efficacy compared to Alogliptin.

KEYWORDS:

DPP-IV inhibitor; In vivo; Pharmacophore hybridization; Superposition; Type 2 diabetes

PMID:
23994324
DOI:
10.1016/j.ejmech.2013.08.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center